Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 6:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,995 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Alzheimer's Disease; Dementia Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions

NCT01028209
View directory record Official record
Conditions
Alzheimer Disease, Parkinson Disease, Multiple Sclerosis
Interventions
[18F] PBR06
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 23, 2026, 6:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Alzheimer's Disease Prevention Trial

NCT00000176
View directory record Official record
Conditions
Alzheimer Disease, Memory Disorders
Interventions
Estrogen, Estrogen and Progesterone
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
65 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2007
U.S. locations
22
States / cities
Birmingham, Alabama • Irvine, California • Stamford, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2010 · Synced Oct 23, 2026, 6:17 AM EDT
Terminated Phase 2 Interventional

A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease

NCT00890890
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Avagacestat, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
45 Years to 90 Years
Enrollment
263 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
50
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 23, 2026, 6:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Treatment and Illness Perceptions Survey (TIPS) II

NCT00059410
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Not listed
Lead sponsor
Alzheimer's Association
Other
Eligibility
Not listed
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 23, 2026, 6:17 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Acupuncture to Reduce Anxiety in Alzheimer's Disease (AD) and AD Related Dementias

NCT03814382
View directory record Official record
Conditions
Alzheimer's Dementia With Behavioral Disturbance
Interventions
Acupuncture needle
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
55 Years to 95 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2022 · Synced Oct 23, 2026, 6:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Early Markers of Cognitive Change and Alzheimer s Disease

NCT01867346
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
60 Years and older
Enrollment
2,850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 23, 2026, 6:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects

NCT02840279
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
BPN14770, Placebo
Drug
Lead sponsor
Tetra Discovery Partners
Industry
Eligibility
25 Years to 90 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 23, 2026, 6:17 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Computerized Tests of Cognitive Decline in Presymptomatic Alzheimer's Disease

NCT04800588
View directory record Official record
Conditions
Alzheimer Disease, Cognitive Decline, Aging
Interventions
California Cognitive Assessment Battery
Diagnostic Test
Lead sponsor
Neurobehavioral Systems, Inc.
Industry
Eligibility
18 Years to 89 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 23, 2026, 6:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Delaying Alzheimer Disease Symptoms With Anti-Inflammatory Drugs

NCT00065169
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
Celecoxib
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years to 90 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 23, 2026, 6:17 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Amyloid Imaging With 11C-PiB in Healthy Aging and Mild Cognitive Impairment

NCT04505735
View directory record Official record
Conditions
Alzheimer Disease, Healthy Aging
Interventions
11C-PiB
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 23, 2026, 6:17 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers

NCT05817643
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
BMS-984923
Drug
Lead sponsor
Allyx Therapeutics
Industry
Eligibility
50 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 23, 2026, 6:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

DELPHI in Subjects at Risk for Stroke and Dementia

NCT03884647
View directory record Official record
Conditions
Stroke, Hypertension, Diabete Mellitus, Dyslipidemias, Sleep Disorder, Smoking, Overweight and Obesity, Familial Alzheimer Disease, Atrial Fibrillation, Cardiac Disease, Cognitive Impairment, Transient Ischemic Attack
Interventions
DELPhI system
Device
Lead sponsor
QuantalX Neuroscience
Industry
Eligibility
50 Years to 75 Years
Enrollment
335 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Walnut Creek, California • Atlanta, Georgia • Norwood, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 23, 2026, 6:17 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of MMFS in Early AD

NCT03531684
View directory record Official record
Conditions
Alzheimer Disease
Interventions
MMFS-205-SR, Placebo
Dietary Supplement
Lead sponsor
Neurocentria, Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 23, 2026, 6:17 AM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab

NCT00916617
View directory record Official record
Conditions
Alzheimer Disease
Interventions
bapineuzumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 89 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Phoenix, Arizona • Encino, California • Delray Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 23, 2026, 6:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects

NCT05225389
View directory record Official record
Conditions
Alzheimer Disease
Interventions
300 mg [C14] CT1812
Drug
Lead sponsor
Cognition Therapeutics
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 23, 2026, 6:17 AM EDT
Completed Not applicable Interventional Results available

Stimulation of Cingulo-opercular Alertness Network

NCT04817891
View directory record Official record
Conditions
Lewy Body Disease, Lewy Body Variant of Alzheimer Disease, Lewy Body Dementia With Behavioral Disturbance
Interventions
HD-tDCS
Device
Lead sponsor
University of Michigan
Other
Eligibility
50 Years to 90 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 23, 2026, 6:17 AM EDT
Completed Not applicable Interventional

Resilient Together for Dementia

NCT06421545
View directory record Official record
Conditions
Alzheimer's Disease and Related Dementias
Interventions
Resilient Together for Dementia
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
65 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 23, 2026, 6:17 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects

NCT00612872
View directory record Official record
Conditions
Parkinson Disease, Alzheimer Disease, Healthy Controls, Multiple Sclerosis
Interventions
[123I]CLINDE
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
30 Years to 50 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 23, 2026, 6:17 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 23, 2026, 6:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)

NCT02754830
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
LY3303560 - IV, Saline Solution - IV, LY3303560 - SC
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
30 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 23, 2026, 6:17 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Electrical Stimulation on Verbal Learning in Typical and Atypical Alzheimer's Disease

NCT04122001
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, Atypical Alzheimer's Disease, Logopenic Progressive Aphasia
Interventions
Active, in-person HD-tDCS or active remote tDCS, Sham, Word List Learning Intervention (WordLLI)
Device · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 23, 2026, 6:17 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention

NCT03859245
View directory record Official record
Conditions
Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Mid-peripheral Drusen Formation, Diabetic Macular Edema (DME)
Interventions
Photobiomodulation, Ketogenic diet
Behavioral
Lead sponsor
Bristlecone Health, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Eagan, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 23, 2026, 6:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.

NCT00938665
View directory record Official record
Conditions
Memory Disorders, Alzheimer Disease, Dementia, Cognitive Impairment, Frontotemporal Dementia
Interventions
COGNISION™ System
Device
Lead sponsor
Neuronetrix, Inc.
Industry
Eligibility
60 Years to 90 Years
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
7
States / cities
West Palm Beach, Florida • Lexington, Kentucky • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 23, 2026, 6:17 AM EDT
Completed Not applicable Interventional

Effect of Testosterone Therapy in Men With Alzheimer's Disease and Low Testosterone

NCT00392912
View directory record Official record
Conditions
Alzheimer's Disease, Hypogonadism
Interventions
AndroGel (Solvay Pharmaceuticals)
Drug
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
55 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2010 · Synced Oct 23, 2026, 6:17 AM EDT